Search: onr:"swepub:oai:gup.ub.gu.se/98699" >
Data from regulator...
-
Ben-Menachem, Elinor,1945Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap, Sektionen för kliniska nervsjukdomar,Institute of Clinical Neurosciences, Section of Neurological Diseases
(author)
Data from regulatory studies: What do they tell? What don't they tell?
- Article/chapterEnglish2005
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/98699
-
https://gup.ub.gu.se/publication/98699URI
-
https://doi.org/10.1111/j.1600-0404.2005.00504.xDOI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Phase III studies of antiepileptic drugs (AEDs) are specifically designed to satisfy strict regulatory criteria. As they are conducted in protocol-restricted patient populations over short treatment periods and employ fixed study designs and dosing schedules, they are not fully representative of 'real-life' clinical practice. Therefore, in order to provide an overall assessment of clinical performance, regulatory studies must be backed up by post-marketing clinical experience. Phase IV studies provide information on a drug's performance in a setting more closely representing real clinical practice, with broader patient populations and a more flexible approach to individual treatment. Prospective long-term studies allow the determination of efficacy and safety (and cost-effectiveness) over extended treatment periods; these studies and audit data provide a means of assessing idiosyncratic side effects, unusual interactions and the effects of an AED in rare patient groups. By complementing regulatory evidence with real-life clinical experience, a comprehensive assessment of the risks and benefits of an AED can be made.
Subject headings and genre
-
Adverse Drug Reaction Reporting Systems
-
Anticonvulsants
-
adverse effects
-
therapeutic use
-
Clinical Trials
-
Phase III as Topic
-
legislation & jurisprudence
-
Clinical Trials
-
Phase IV as Topic
-
legislation & jurisprudence
-
Drug Approval
-
legislation & jurisprudence
-
Drug Interactions
-
Epilepsy
-
drug therapy
-
Follow-Up Studies
-
Humans
-
Product Surveillance
-
Postmarketing
-
Prospective Studies
-
Risk Assessment
-
Treatment Outcome
-
United States
Added entries (persons, corporate bodies, meetings, titles ...)
-
Göteborgs universitetInstitutionen för klinisk neurovetenskap, Sektionen för kliniska nervsjukdomar
(creator_code:org_t)
Related titles
-
In:Acta neurologica Scandinavica. Supplementum: Hindawi Limited181, s. 21-50065-14270001-63141600-0404
Internet link
Find in a library
To the university's database